{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:55:00Z","timestamp":1790222100955,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-024-03744-x","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T05:52:35Z","timestamp":1732168355000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Strategic interventions in clinical randomized trials for metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity in the pediatric population: a systematic review with meta-analysis and bibliometric analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Isabel","family":"Oma\u00f1a-Guzm\u00e1n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisol","family":"Rosas-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoscelina Estrella","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Monserrat","family":"Perez-Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Diaz-Badillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Alanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Bustamante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Octelina","family":"Castillo-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"del Toro-Cisneros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego Armando","family":"Esquivel-Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Garcia-Villalobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayely","family":"Garibay-Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza Milagros","family":"Garcia-Oropesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Hernandez-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Beatriz","family":"Lopez-Sosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Membreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar Omar","family":"Moctezuma-Chavez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia X.","family":"Munguia-Cisneros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edna J.","family":"Nava-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana L.","family":"Perales-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"P\u00e9rez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Rivera-Marrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisha","family":"Valdez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso Alejandro","family":"V\u00e1zquez-Ch\u00e1vez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Ramirez-Pfeiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen V.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Tapia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonel","family":"Vela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0966-8766","authenticated-orcid":false,"given":"Juan Carlos","family":"Lopez-Alvarenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"key":"3744_CR1","doi-asserted-by":"publisher","unstructured":"Iqbal U, Perumpail BJ, Akhtar D, Kim D, Ahmed A. The epidemiology, risk profiling and diagnostic challenges of nonalcoholic fatty liver disease. Medicines (Basel). 2019;6(41). https:\/\/doi.org\/10.3390\/medicines6010041.","DOI":"10.3390\/medicines6010041"},{"issue":"10","key":"3744_CR2","doi-asserted-by":"publisher","first-page":"e0140908","DOI":"10.1371\/journal.pone.0140908","volume":"10","author":"EL Anderson","year":"2015","unstructured":"Anderson EL, Howe LD, Jones HE, Higgins JP, Lawlor DA, Fraser A. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS ONE. 2015;10(10):e0140908.","journal-title":"PLoS ONE"},{"issue":"1","key":"3744_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0038-1627456","volume":"38","author":"JP Mann","year":"2018","unstructured":"Mann JP, Valenti L, Scorletti E, Byrne CD, Nobili V. Nonalcoholic fatty liver disease in children. Semin Liver Dis. 2018;38(1):1\u201313.","journal-title":"Semin Liver Dis"},{"key":"3744_CR4","doi-asserted-by":"publisher","unstructured":"Umemura A, Kataoka S, Okuda K, Seko Y, Yamaguchi K, Moriguchi M, et al. Potential therapeutic targets and promising agents for combating NAFLD. Biomedicines. 2022;10(901). https:\/\/doi.org\/10.3390\/biomedicines10040901.","DOI":"10.3390\/biomedicines10040901"},{"issue":"7","key":"3744_CR5","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1053\/j.gastro.2020.01.048","volume":"158","author":"D Goldner","year":"2020","unstructured":"Goldner D, Lavine JE. Nonalcoholic fatty liver disease in children: unique considerations and challenges. Gastroenterology. 2020;158(7):1967-83 e1.","journal-title":"Gastroenterology"},{"issue":"2","key":"3744_CR6","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/hep.32403","volume":"76","author":"MB Vos","year":"2022","unstructured":"Vos MB, Van Natta ML, Blondet NM, Dasarathy S, Fishbein M, Hertel P, et al. Randomized placebo-controlled trial of losartan for pediatric NAFLD. Hepatology. 2022;76(2):429\u201344.","journal-title":"Hepatology"},{"key":"3744_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jclinepi.2015.02.019","volume":"73","author":"L Perrier","year":"2016","unstructured":"Perrier L, Lightfoot D, Kealey MR, Straus SE, Tricco AC. Knowledge synthesis research: a bibliometric analysis. J Clin Epidemiol. 2016;73:50\u20137.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"3744_CR8","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/0194262X.2021.1991547","volume":"41","author":"JT McAllister","year":"2022","unstructured":"McAllister JT, Lennertz L, Atencio MZ. Mapping a discipline: a guide to using VOSviewer for bibliometric and visual analysis. Sci Technol Libr. 2022;41(3):319\u201348.","journal-title":"Sci Technol Libr"},{"key":"3744_CR9","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"3744_CR10","unstructured":"A systematic review with meta-analysis: clinical randomized trials for NASH and obesity in pediatric population. NIHR; 2023. https:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.php?RecordID=393952. Accesed 19 Dec 2023."},{"issue":"3","key":"3744_CR11","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.jpeds.2012.09.012","volume":"162","author":"E Leclercq","year":"2013","unstructured":"Leclercq E, Leeflang MM, van Dalen EC, Kremer LC. Validation of search filters for identifying pediatric studies in PubMed. J Pediatr. 2013;162(3):629-34 e2.","journal-title":"J Pediatr"},{"issue":"1","key":"3744_CR12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.","journal-title":"Syst Rev"},{"issue":"1","key":"3744_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1\u201312.","journal-title":"Control Clin Trials"},{"key":"3744_CR14","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"3744_CR15","volume-title":"Meta-analysis in Stata","author":"TM Palmer","year":"2009","unstructured":"Palmer TM, Newton HJ. Meta-analysis in Stata. College Station, TX: Stata Press; 2009."},{"issue":"1","key":"3744_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1136\/eb-2014-102035","volume":"18","author":"A Chaimani","year":"2015","unstructured":"Chaimani A. Accounting for baseline differences in meta-analysis. Evid Based Ment Health. 2015;18(1):23\u20136.","journal-title":"Evid Based Ment Health"},{"issue":"2","key":"3744_CR17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3102\/10769986006002107","volume":"6","author":"LV Hedges","year":"1981","unstructured":"Hedges LV. Distribution theory for Glass\u2019s estimator of effect size and related estimators. J Educ Stat. 1981;6(2):107\u201328.","journal-title":"J Educ Stat"},{"issue":"2","key":"3744_CR18","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","volume":"84","author":"NJ van Eck","year":"2010","unstructured":"van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523\u201338.","journal-title":"Scientometrics"},{"key":"3744_CR19","volume-title":"Citation analysis in research evaluation","author":"FM Henk","year":"2005","unstructured":"Henk FM. Citation analysis in research evaluation. Dordrecht: Springer; 2005."},{"issue":"12","key":"3744_CR20","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.15252\/embr.201439608","volume":"15","author":"L Bornmann","year":"2014","unstructured":"Bornmann L, Leydesdorff L. Scientometrics in a changing research landscape: bibliometrics has become an integral part of research quality evaluation and has been changing the practice of research. EMBO Rep. 2014;15(12):1228\u201332.","journal-title":"EMBO Rep"},{"issue":"4","key":"3744_CR21","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.joi.2015.08.001","volume":"9","author":"L Waltman","year":"2015","unstructured":"Waltman L, van Eck NJ. Field-normalized citation impact indicators and the choice of an appropriate counting method. J Informet. 2015;9(4):872\u201394.","journal-title":"J Informet"},{"issue":"6","key":"3744_CR22","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1024\/0300-9831\/a000086","volume":"81","author":"M Akcam","year":"2011","unstructured":"Akcam M, Boyaci A, Pirgon O, Kaya S, Uysal S, Dundar BN. Therapeutic effect of metformin and vitamin E versus prescriptive diet in obese adolescents with fatty liver. Int J Vitam Nutr Res. 2011;81(6):398\u2013406.","journal-title":"Int J Vitam Nutr Res"},{"issue":"16","key":"3744_CR23","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1001\/jama.2011.520","volume":"305","author":"JE Lavine","year":"2011","unstructured":"Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305(16):1659\u201368.","journal-title":"JAMA"},{"issue":"1","key":"3744_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.47203\/IJCH.2019.v31i01.009","volume":"31","author":"P Goyal","year":"2019","unstructured":"Goyal P, Thapa BR, Sharma NR, Bhatia A. The effect of probiotic and lifestyle modification in obese pediatrics with non-alcoholic fatty liver disease. Indian J Comm Health. 2019;31(1):50\u20136.","journal-title":"Indian J Comm Health"},{"issue":"11\u201312","key":"3744_CR25","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/j.1365-2036.2006.03161.x","volume":"24","author":"V Nobili","year":"2006","unstructured":"Nobili V, Manco M, Devito R, Ciampalini P, Piemonte F, Marcellini M. Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2006;24(11\u201312):1553\u201361.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"3744_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/hep.22336","volume":"48","author":"V Nobili","year":"2008","unstructured":"Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology. 2008;48(1):119\u201328.","journal-title":"Hepatology"},{"issue":"4","key":"3744_CR27","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1136\/adc.2010.192401","volume":"96","author":"V Nobili","year":"2011","unstructured":"Nobili V, Bedogni G, Alisi A, Pietrobattista A, Rise P, Galli C, et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child. 2011;96(4):350\u20133.","journal-title":"Arch Dis Child"},{"issue":"11","key":"3744_CR28","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.numecd.2012.10.010","volume":"23","author":"V Nobili","year":"2013","unstructured":"Nobili V, Alisi A, Della Corte C, Rise P, Galli C, Agostoni C, et al. Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children. Nutr Metab Cardiovasc Dis. 2013;23(11):1066\u201370.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"1","key":"3744_CR29","doi-asserted-by":"publisher","first-page":"62","DOI":"10.17795\/compreped-6249","volume":"4","author":"R Ghergherehchi","year":"2012","unstructured":"Ghergherehchi R, Hazhir N, Mostafa GM. Lifestyle intervention and vitamin E therapy in obese children with nonalcoholic fatty liver disease. J Compr Ped. 2012;4(1):62\u20135.","journal-title":"J Compr Ped"},{"issue":"11","key":"3744_CR30","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1111\/apt.12758","volume":"39","author":"A Alisi","year":"2014","unstructured":"Alisi A, Bedogni G, Baviera G, Giorgio V, Porro E, Paris C, et al. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2014;39(11):1276\u201385.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"3744_CR31","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.jpeds.2015.01.056","volume":"166","author":"W Janczyk","year":"2015","unstructured":"Janczyk W, Lebensztejn D, Wierzbicka-Rucinska A, Mazur A, Neuhoff-Murawska J, Matusik P, et al. Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial. J Pediatr. 2015;166(6):1358-63 e1-3.","journal-title":"J Pediatr"},{"issue":"7","key":"3744_CR32","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/ijo.2015.40","volume":"39","author":"A Miccheli","year":"2015","unstructured":"Miccheli A, Capuani G, Marini F, Tomassini A, Pratico G, Ceccarelli S, et al. Urinary (1)H-NMR-based metabolic profiling of children with NAFLD undergoing VSL#3 treatment. Int J Obes (Lond). 2015;39(7):1118\u201325.","journal-title":"Int J Obes (Lond)"},{"issue":"8","key":"3744_CR33","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.numecd.2015.04.003","volume":"25","author":"L Pacifico","year":"2015","unstructured":"Pacifico L, Bonci E, Di Martino M, Versacci P, Andreoli G, Silvestri LM, et al. A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2015;25(8):734\u201341.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"12","key":"3744_CR34","doi-asserted-by":"publisher","first-page":"e0168216","DOI":"10.1371\/journal.pone.0168216","volume":"11","author":"C Della Corte","year":"2016","unstructured":"Della Corte C, Carpino G, De Vito R, De Stefanis C, Alisi A, Cianfarani S, et al. Docosahexanoic acid plus vitamin D treatment improves features of NAFLD in children with serum vitamin D deficiency: results from a single centre trial. PLoS ONE. 2016;11(12):e0168216.","journal-title":"PLoS ONE"},{"issue":"1","key":"3744_CR35","first-page":"16","volume":"6","author":"F Famouri","year":"2017","unstructured":"Famouri F, Salehi MM, Rostampour N, Hashemi E, Shahsanaee A. The effect of silymarin on non-alcoholic fatty liver disease of children. J Herbmed Pharmacol. 2017;6(1):16\u201320.","journal-title":"J Herbmed Pharmacol"},{"issue":"3","key":"3744_CR36","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/MPG.0000000000001422","volume":"64","author":"F Famouri","year":"2017","unstructured":"Famouri F, Shariat Z, Hashemipour M, Keikha M, Kelishadi R. Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents. J Pediatr Gastroenterol Nutr. 2017;64(3):413\u20137.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"3744_CR37","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1089\/ars.2018.7704","volume":"31","author":"V Nobili","year":"2019","unstructured":"Nobili V, Alisi A, Mosca A, Crudele A, Zaffina S, Denaro M, et al. The antioxidant effects of hydroxytyrosol and vitamin E on pediatric nonalcoholic fatty liver disease, in a clinical trial: a new treatment? Antioxid Redox Signal. 2019;31(2):127\u201333.","journal-title":"Antioxid Redox Signal"},{"issue":"2","key":"3744_CR38","doi-asserted-by":"publisher","first-page":"187","DOI":"10.5223\/pghn.2021.24.2.187","volume":"24","author":"K Namakin","year":"2021","unstructured":"Namakin K, Hosseini M, Zardast M, Mohammadifard M. Vitamin D effect on ultrasonography and laboratory indices and biochemical indicators in the blood: an interventional study on 12 to 18-year-old children with fatty liver. Pediatr Gastroenterol Hepatol Nutr. 2021;24(2):187\u201396.","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"issue":"7","key":"3744_CR39","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1515\/jpem-2020-0642","volume":"34","author":"H Saneian","year":"2021","unstructured":"Saneian H, Khalilian L, Heidari-Beni M, Khademian M, Famouri F, Nasri P, et al. Effect of l-carnitine supplementation on children and adolescents with nonalcoholic fatty liver disease (NAFLD): a randomized, triple-blind, placebo-controlled clinical trial. J Pediatr Endocrinol Metab. 2021;34(7):897\u2013904.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"6","key":"3744_CR40","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3345\/cep.2021.00787","volume":"65","author":"T Rodrigo","year":"2022","unstructured":"Rodrigo T, Dulani S, Nimali Seneviratne S, De Silva AP, Fernando J, De Silva HJ, et al. Effects of probiotics combined with dietary and lifestyle modification on clinical, biochemical, and radiological parameters in obese children with nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis: a randomized clinical trial. Clin Exp Pediatr. 2022;65(6):304\u201311.","journal-title":"Clin Exp Pediatr"},{"issue":"2","key":"3744_CR41","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00431-021-04243-4","volume":"181","author":"D El Amrousy","year":"2022","unstructured":"El Amrousy D, Abdelhai D, Shawky D. Vitamin D and nonalcoholic fatty liver disease in children: a randomized controlled clinical trial. Eur J Pediatr. 2022;181(2):579\u201386.","journal-title":"Eur J Pediatr"},{"issue":"10","key":"3744_CR42","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.3748\/wjg.14.1598","volume":"14","author":"CL Wang","year":"2008","unstructured":"Wang CL, Liang L, Fu JF, Zou CC, Hong F, Xue JZ, et al. Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children. World J Gastroenterol. 2008;14(10):1598\u2013602.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"3744_CR43","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3390\/jcm9010141","volume":"9","author":"R Negri","year":"2020","unstructured":"Negri R, Trinchese G, Carbone F, Caprio MG, Stanzione G, di Scala C, et al. Randomised clinical trial: calorie restriction regimen with tomato juice supplementation ameliorates oxidative stress and preserves a proper immune surveillance modulating mitochondrial bioenergetics of T-lymphocytes in obese children affected by non-alcoholic fatty liver disease (NAFLD). J Clin Med. 2020;9(1):141.","journal-title":"J Clin Med"},{"issue":"4","key":"3744_CR44","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1177\/0260106017720350","volume":"23","author":"CT de Lira","year":"2017","unstructured":"de Lira CT, Dos Santos MA, Gomes PP, Fidelix YL, Dos Santos AC, Tenorio TR, et al. Aerobic training performed at ventilatory threshold improves liver enzymes and lipid profile related to non-alcoholic fatty liver disease in adolescents with obesity. Nutr Health. 2017;23(4):281\u20138.","journal-title":"Nutr Health"},{"issue":"9","key":"3744_CR45","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1038\/s41366-018-0010-8","volume":"42","author":"DFY Chan","year":"2018","unstructured":"Chan DFY, So HK, Hui SCN, Chan RSM, Li AM, Sea MM, et al. Dietitian-led lifestyle modification programme for obese Chinese adolescents with non-alcoholic fatty liver disease: a randomized controlled study. Int J Obes (Lond). 2018;42(9):1680\u201390.","journal-title":"Int J Obes (Lond)"},{"issue":"7","key":"3744_CR46","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1093\/jn\/nxac046","volume":"152","author":"KA Schmidt","year":"2022","unstructured":"Schmidt KA, Jones RB, Rios C, Corona Y, Berger PK, Plows JF, et al. Clinical intervention to reduce dietary sugar does not affect liver fat in latino youth, regardless of PNPLA3 genotype: a randomized controlled trial. J Nutr. 2022;152(7):1655\u201365.","journal-title":"J Nutr"},{"issue":"4","key":"3744_CR47","doi-asserted-by":"publisher","first-page":"e12872","DOI":"10.1111\/ijpo.12872","volume":"17","author":"G Yurtdas","year":"2022","unstructured":"Yurtdas G, Akbulut G, Baran M, Yilmaz C. The effects of Mediterranean diet on hepatic steatosis, oxidative stress, and inflammation in adolescents with non-alcoholic fatty liver disease: a randomized controlled trial. Pediatr Obes. 2022;17(4):e12872.","journal-title":"Pediatr Obes"},{"key":"3744_CR48","doi-asserted-by":"publisher","unstructured":"Cohen CC, Li KW, Alazraki AL, Beysen C, Carrier CA, Cleeton RL, et al. Dietary sugar restriction reduces hepatic de novo lipogenesis in adolescent boys with fatty liver disease. J Clin Invest. 2021;131(24):e150996. https:\/\/doi.org\/10.1172\/JCI150996.","DOI":"10.1172\/JCI150996"},{"issue":"3","key":"3744_CR49","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/09637486.2021.1979478","volume":"73","author":"UE Akbulut","year":"2022","unstructured":"Akbulut UE, Isik IA, Atalay A, Eraslan A, Durmus E, Turkmen S, et al. The effect of a Mediterranean diet vs. a low-fat diet on non-alcoholic fatty liver disease in children: a randomized trial. Int J Food Sci Nutr. 2022;73(3):357\u201366.","journal-title":"Int J Food Sci Nutr."},{"issue":"3","key":"3744_CR50","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1001\/jama.2018.20579","volume":"321","author":"JB Schwimmer","year":"2019","unstructured":"Schwimmer JB, Ugalde-Nicalo P, Welsh JA, Angeles JE, Cordero M, Harlow KE, et al. Effect of a low free sugar diet vs usual diet on nonalcoholic fatty liver disease in adolescent boys: a randomized clinical trial. JAMA. 2019;321(3):256\u201365.","journal-title":"JAMA"},{"issue":"8","key":"3744_CR51","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.3390\/nu6083187","volume":"6","author":"R Jin","year":"2014","unstructured":"Jin R, Welsh JA, Le NA, Holzberg J, Sharma P, Martin DR, et al. Dietary fructose reduction improves markers of cardiovascular disease risk in Hispanic-American adolescents with NAFLD. Nutrients. 2014;6(8):3187\u2013201.","journal-title":"Nutrients"},{"issue":"2","key":"3744_CR52","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/MPG.0000000000001482","volume":"64","author":"MB Vos","year":"2017","unstructured":"Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the expert committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017;64(2):319\u201334.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"9","key":"3744_CR53","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.3390\/nu10091153","volume":"10","author":"AFG Cicero","year":"2018","unstructured":"Cicero AFG, Colletti A, Bellentani S. Nutraceutical approach to non-alcoholic fatty liver disease (NAFLD): the available clinical evidence. Nutrients. 2018;10(9):1153.","journal-title":"Nutrients"},{"key":"3744_CR54","doi-asserted-by":"publisher","first-page":"7643542","DOI":"10.1155\/2019\/7643542","volume":"2019","author":"S Zhu","year":"2019","unstructured":"Zhu S, Wang Y, Luo F, Liu J, Xiu L, Qin J, et al. The level of vitamin D in children and adolescents with nonalcoholic fatty liver disease: a meta-analysis. Biomed Res Int. 2019;2019:7643542.","journal-title":"Biomed Res Int"},{"key":"3744_CR55","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.pharmthera.2017.07.007","volume":"181","author":"DB Jump","year":"2018","unstructured":"Jump DB, Lytle KA, Depner CM, Tripathy S. Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease. Pharmacol Ther. 2018;181:108\u201325.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"3744_CR56","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/jgh.15221","volume":"36","author":"A Vadarlis","year":"2021","unstructured":"Vadarlis A, Antza C, Bakaloudi DR, Doundoulakis I, Kalopitas G, Samara M, et al. Systematic review with meta-analysis: the effect of vitamin E supplementation in adult patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2021;36(2):311\u20139.","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"3744_CR57","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.advnut.2023.04.011","volume":"14","author":"JF Lopez-Gil","year":"2023","unstructured":"Lopez-Gil JF, Garcia-Hermoso A, Sotos-Prieto M, Cavero-Redondo I, Martinez-Vizcaino V, Kales SN. Mediterranean diet-based interventions to improve anthropometric and obesity indicators in children and adolescents: a systematic review with meta-analysis of randomized controlled trials. Adv Nutr. 2023;14(4):858\u201369.","journal-title":"Adv Nutr"},{"issue":"3","key":"3744_CR58","first-page":"275","volume":"11","author":"E Choi","year":"2024","unstructured":"Choi E, Ramirez Tovar A, He Z, Soler Rodriguez DM, Vos MB, Arora S, et al. Glucagon-like Peptide-1 receptor agonists-a potential new medication for pediatric metabolic-dysfunction-associated steatotic liver disease (MASLD). Children (Basel). 2024;11(3):275.","journal-title":"Children (Basel)"},{"issue":"1","key":"3744_CR59","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2337\/dsi23-0012","volume":"37","author":"I Genua","year":"2024","unstructured":"Genua I, Cusi K. Pharmacological approaches to nonalcoholic fatty liver disease: current and future therapies. Diabetes Spectr. 2024;37(1):48\u201358.","journal-title":"Diabetes Spectr"},{"issue":"18","key":"3744_CR60","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","volume":"362","author":"AJ Sanyal","year":"2010","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675\u201385.","journal-title":"N Engl J Med"},{"issue":"7","key":"3744_CR61","first-page":"407","volume":"14","author":"J Shah","year":"2018","unstructured":"Shah J, Okubote T, Alkhouri N. Overview of updated practice guidelines for pediatric nonalcoholic fatty liver disease. Gastroenterol Hepatol (N Y). 2018;14(7):407\u201314.","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"2","key":"3744_CR62","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ueg2.12525","volume":"12","author":"J Zeng","year":"2024","unstructured":"Zeng J, Fan JG, Francque SM. Therapeutic management of metabolic dysfunction associated steatotic liver disease. United Eur Gastroenterol J. 2024;12(2):177\u201386.","journal-title":"United Eur Gastroenterol J"},{"issue":"9436","key":"3744_CR63","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(04)16942-0","volume":"364","author":"PH Caldwell","year":"2004","unstructured":"Caldwell PH, Murphy SB, Butow PN, Craig JC. Clinical trials in children. Lancet. 2004;364(9436):803\u201311.","journal-title":"Lancet"},{"key":"3744_CR64","unstructured":"Field MJ, Behrman RE. Ethical conduct of clinical research involving children. Children CoCRI, editor. Washington (DC): National Academies Press (US); 2004."},{"key":"3744_CR65","doi-asserted-by":"crossref","unstructured":"Gl\u00e4nzel W, Schubert A. Analysing scientific networks through co-authorship. In: Moed HF, Gl\u00e4nzel W, Schmoch U, editors. Handbook of quantitative science and technology research: the use of publication and patent statistics in studies of S&T systems. Dordrecht: Springer Netherlands; 2005:257\u201376.","DOI":"10.1007\/1-4020-2755-9_12"},{"key":"3744_CR66","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jbusres.2022.04.042","volume":"148","author":"D Mukherjee","year":"2022","unstructured":"Mukherjee D, Lim WM, Kumar S, Donthu N. Guidelines for advancing theory and practice through bibliometric research. J Bus Res. 2022;148:101\u201315.","journal-title":"J Bus Res"},{"key":"3744_CR67","doi-asserted-by":"publisher","first-page":"665023","DOI":"10.3389\/fmed.2021.665023","volume":"8","author":"EM Garcia-Oropesa","year":"2021","unstructured":"Garcia-Oropesa EM, Martinez-Lopez YE, Ruiz-Cejudo SM, Martinez-Ezquerro JD, Diaz-Badillo A, Ramirez-Pfeiffer C, et al. Looking for crumbs in the obesity forest: anti-obesity interventions and obesity-associated cardiometabolic traits in the Mexican population. History and systematic review with meta-analyses. Front Med (Lausanne). 2021;8:665023.","journal-title":"Front Med (Lausanne)"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03744-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-024-03744-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03744-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T07:04:09Z","timestamp":1732172649000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-024-03744-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3744"],"URL":"https:\/\/doi.org\/10.1186\/s12916-024-03744-x","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,21]]},"assertion":[{"value":"14 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This meta-analysis did not involve any direct interaction with human or animal subjects; it exclusively utilized publicly available data from previously published studies.Consequently, there was no requirement for Institutional Review Board (IRB) approval. The protocol was registered in PROSPERO (CRD42023393952) to ensure methodological transparency and to adhere to best practices in systematic review research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests. They do not work for private laboratories and have not received any payments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"548"}}